Thomas W Loewald
CIK 1538555 · Senior Vice President · last filed 2024-05-23
Thomas W Loewald is a Senior Vice President who has filed 61 SEC Form 4 insider transactions across 2 companies since 2012. The most recent filing, for HBIO, was dated May 23, 2024. Across all open-market trades the lifetime net is −$18.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $23.5M across reported positions. 18 SEC filings were submitted jointly with HARVARD BIOSCIENCE INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$23.49M
2
61
-$18.05M
Filer Profile
WALTHAM, MA 02451
Holdings By Company
Recent Filings
61 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-23 | HBIO | Grant (A) | +45,872 | $0 | EDGAR |
| 2023-05-23 | HBIO | Grant (A) | +25,554 | $0 | EDGAR |
| 2022-05-26 | HBIO | Grant (A) | +38,259 | $0 | EDGAR |
| 2022-01-03 | HBIO | Grant (A) | +2,525 | $0 | EDGAR |
| 2021-12-29 | HBIO | Grant (A) | +1,401 | $0 | EDGAR |
| 2021-05-27 | HBIO | Grant (A) | +14,400 | $0 | EDGAR |
| 2021-01-06 | HBIO | Grant (A) | +15,300 | $0 | EDGAR |
| 2020-06-19 | HBIO | Grant (A) | +28,100 | $0 | EDGAR |
| 2020-01-03 | HBIO | Grant (A) | +20,700 | $0 | EDGAR |
| 2019-08-20 | HBIO | Buy (P) | +20,000 | $50.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.